Elite Pharmaceuticals Inc (ELTP)

[The ELTP King]

Now 93% of all opioid prescriptions are IR products. Used to be 90% or 91%.

In 2016, 93% of all prescriptions for oral opioid analgesics in the United States were for IR products.

Given the greater exposure of IR products in the community, it is not surprising that population-adjusted rates of intentional abuse are 4.6 times greater and rates of drug diversion are 6.1 times greater for IR products than ER products.

For IR oxycodone, specifically, the population-adjusted rates of intentional abuse are 2.9 times higher than that of ER oxycodone and 6.8 times higher than that of ER morphine.

Conclusion

Despite the fact that the population-adjusted rate of abuse of IR products is over 4 times greater
than ER products, there are currently no abuse-deterrent IR opioid products approved in the US.

IR oxycodone, specifically, is a common target of abuse with relatively high rates of intranasal
and IV routes of abuse compared to other opioid products.